

## **SUMMARY OF MATERIAL MODIFICATIONS**

### **COVERAGE OF RSV VACCINES**

**To: All Active Participants and Retirees**

**From: The Board of Trustees of the Welfare Fund of Engineers Local 513**

**Re: Coverage of RSV Vaccines**

Effective June 1, 2024, respiratory syncytial virus (RSV) vaccines will be covered at 100% for all eligible dependents under the age of 2 (0 – 24 months old).

The RSV vaccine Beyfortus (Nirsevimab) has been approved by the U.S. Food and Drug Administration (FDA) for infants younger than 8 months of age born during RSV season or entering their first RSV season and children aged 8 through 19 months who are at increased risk for severe RSV disease and entering their second RSV season. The RSV vaccine Synagis (Palivizumab) has also been approved by the FDA for children younger than age 24 months of age with certain conditions that place them at increased risk for severe RSV disease. Synagis must be given once a month during RSV season. Both of these vaccines will be covered at 100% for those eligible.

Note that if more RSV vaccines are approved and recommended by the FDA, they will also be covered at 100%.

This Summary of Material Modifications is only intended to provide a brief overview of the changes made to the Welfare Fund. The terms of the Welfare Fund are governed by the Plan Document. Please contact the Benefit Office at (314) 739-2973 for any questions regarding this summary.